JP2012512903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512903A5 JP2012512903A5 JP2011542487A JP2011542487A JP2012512903A5 JP 2012512903 A5 JP2012512903 A5 JP 2012512903A5 JP 2011542487 A JP2011542487 A JP 2011542487A JP 2011542487 A JP2011542487 A JP 2011542487A JP 2012512903 A5 JP2012512903 A5 JP 2012512903A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino acid
- group
- hydrogen
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 74
- 235000001014 amino acid Nutrition 0.000 claims 71
- 150000001413 amino acids Chemical class 0.000 claims 59
- 229910052739 hydrogen Inorganic materials 0.000 claims 49
- 239000001257 hydrogen Substances 0.000 claims 40
- 238000006467 substitution reaction Methods 0.000 claims 30
- 125000003275 alpha amino acid group Chemical group 0.000 claims 26
- 150000002431 hydrogen Chemical class 0.000 claims 25
- 108060003199 Glucagon Proteins 0.000 claims 21
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 20
- 239000000651 prodrug Substances 0.000 claims 19
- 229940002612 prodrug Drugs 0.000 claims 19
- 125000004429 atom Chemical group 0.000 claims 18
- 125000000623 heterocyclic group Chemical group 0.000 claims 16
- 102000051325 Glucagon Human genes 0.000 claims 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 15
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 15
- 229960004666 glucagon Drugs 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 14
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 14
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 13
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims 12
- 230000004048 modification Effects 0.000 claims 12
- 238000012986 modification Methods 0.000 claims 12
- -1 aromatic amino acid Chemical class 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 8
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 8
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 8
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 7
- 230000007017 scission Effects 0.000 claims 7
- VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 6
- CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000002252 acyl group Chemical group 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 150000002148 esters Chemical group 0.000 claims 5
- 235000013922 glutamic acid Nutrition 0.000 claims 5
- 239000004220 glutamic acid Substances 0.000 claims 5
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical compound OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 4
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 235000018417 cysteine Nutrition 0.000 claims 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 229960003104 ornithine Drugs 0.000 claims 4
- 230000004962 physiological condition Effects 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- XABCFXXGZPWJQP-UHFFFAOYSA-N 3-aminoadipic acid Chemical compound OC(=O)CC(N)CCC(O)=O XABCFXXGZPWJQP-UHFFFAOYSA-N 0.000 claims 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 125000005599 alkyl carboxylate group Chemical group 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 150000007942 carboxylates Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 150000003568 thioethers Chemical class 0.000 claims 2
- DNIFHMZTVZPEHP-VIFPVBQESA-N (2s)-2-[amino(naphthalen-1-yl)amino]propanoic acid Chemical compound C1=CC=C2C(N(N)[C@@H](C)C(O)=O)=CC=CC2=C1 DNIFHMZTVZPEHP-VIFPVBQESA-N 0.000 claims 1
- YJLGBPOTRWZBFH-JTQLQIEISA-N (2s)-2-hydrazinyl-3-(1h-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NN)C(O)=O)=CNC2=C1 YJLGBPOTRWZBFH-JTQLQIEISA-N 0.000 claims 1
- XJPHGGXFBWOHFL-QMMMGPOBSA-N (2s)-2-hydrazinyl-3-(4-hydroxyphenyl)propanoic acid Chemical compound NN[C@H](C(O)=O)CC1=CC=C(O)C=C1 XJPHGGXFBWOHFL-QMMMGPOBSA-N 0.000 claims 1
- AWPUZQSFPGSJPM-UHFFFAOYSA-N 2-(n-aminoanilino)acetic acid Chemical compound OC(=O)CN(N)C1=CC=CC=C1 AWPUZQSFPGSJPM-UHFFFAOYSA-N 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 1
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 1
- 108010015792 glycyllysine Proteins 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003458 sulfonic acid derivatives Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- 0 CC(C)(C(C)=O)N(*)C(C(C)(*)*)=O Chemical compound CC(C)(C(C)=O)N(*)C(C(C)(*)*)=O 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13921008P | 2008-12-19 | 2008-12-19 | |
| US61/139,210 | 2008-12-19 | ||
| US14427109P | 2009-01-13 | 2009-01-13 | |
| US61/144,271 | 2009-01-13 | ||
| US18755609P | 2009-06-16 | 2009-06-16 | |
| US61/187,556 | 2009-06-16 | ||
| PCT/US2009/068745 WO2010071807A1 (en) | 2008-12-19 | 2009-12-18 | Amide based glucagon superfamily peptide prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095017A Division JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012512903A JP2012512903A (ja) | 2012-06-07 |
| JP2012512903A5 true JP2012512903A5 (enExample) | 2013-02-21 |
Family
ID=42269125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011542487A Pending JP2012512903A (ja) | 2008-12-19 | 2009-12-18 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
| JP2015095017A Pending JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015095017A Pending JP2015180649A (ja) | 2008-12-19 | 2015-05-07 | アミド系グルカゴンスーパーファミリーペプチドプロドラッグ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8969288B2 (enExample) |
| EP (2) | EP2376097A4 (enExample) |
| JP (2) | JP2012512903A (enExample) |
| KR (1) | KR20110110174A (enExample) |
| CN (1) | CN102325539A (enExample) |
| AR (1) | AR074811A1 (enExample) |
| AU (1) | AU2009327418A1 (enExample) |
| BR (1) | BRPI0922969A2 (enExample) |
| CA (1) | CA2747499A1 (enExample) |
| CL (1) | CL2011001498A1 (enExample) |
| IL (1) | IL213113A (enExample) |
| MX (1) | MX2011006524A (enExample) |
| PE (1) | PE20120332A1 (enExample) |
| RU (1) | RU2550696C2 (enExample) |
| SG (1) | SG172291A1 (enExample) |
| TW (1) | TWI489992B (enExample) |
| WO (1) | WO2010071807A1 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| JP5890085B2 (ja) | 2007-01-05 | 2016-03-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| AU2008318876B2 (en) | 2007-10-30 | 2014-05-15 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| EP2217701B9 (en) | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon antagonists |
| AU2009210570B2 (en) * | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| CL2009001425A1 (es) * | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal. |
| EP2307037A4 (en) * | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| US8697632B2 (en) | 2008-12-19 | 2014-04-15 | Indiana University Research And Technology Corporation | Amide based insulin prodrugs |
| US8481485B2 (en) | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| CA2747499A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| RU2578591C2 (ru) * | 2008-12-19 | 2016-03-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Лекарственные средства, связанные с дипептидами |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| AU2011268327B2 (en) | 2010-06-16 | 2016-02-25 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | アミド系インスリンプロドラッグ |
| CA2796879A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
| WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
| AR084558A1 (es) | 2010-12-22 | 2013-05-22 | Marcadia Biotech | Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1) |
| PE20240686A1 (es) | 2011-06-10 | 2024-04-10 | Hanmi Science Co Ltd | Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1) |
| JP5914641B2 (ja) * | 2011-06-10 | 2016-05-11 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | グルコース依存性インスリン分泌刺激ポリペプチドのアナログ、医薬組成物及びその使用 |
| KR101577734B1 (ko) | 2011-06-17 | 2015-12-29 | 한미사이언스 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도 |
| PE20140724A1 (es) * | 2011-06-22 | 2014-07-10 | Univ Indiana Res & Tech Corp | Coagonistas del receptor de glucagon/glp-1 |
| KR20140043793A (ko) | 2011-06-22 | 2014-04-10 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-작용물질 |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| EP2578599A1 (en) | 2011-10-07 | 2013-04-10 | LanthioPep B.V. | Cyclic analogs of GLP-1 and GLP-1 related peptides |
| ES2672880T3 (es) | 2011-11-17 | 2018-06-18 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor de glucocorticoides |
| CN104114183A (zh) | 2011-12-20 | 2014-10-22 | 印第安纳大学研究及科技有限公司 | 用于治疗糖尿病的基于ctp的胰岛素类似物 |
| DK2802598T3 (en) * | 2012-01-12 | 2018-03-12 | Univ Ulster | PEPTIDES AND PEPTID DERIVATIVES BASED ON XENIN |
| CN104185639B (zh) | 2012-03-01 | 2018-06-19 | 诺和诺德股份有限公司 | Glp-1前体药物 |
| RU2015101697A (ru) | 2012-06-21 | 2016-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, обладающие активностью рецептора gip |
| BR112014031671A2 (pt) | 2012-06-21 | 2018-08-07 | Hoffmann La Roche | análogos de glucagon exibindo atividade de receptor gip |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| CN104981251B (zh) | 2012-09-26 | 2018-03-20 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| PL2916819T3 (pl) * | 2012-11-06 | 2020-01-31 | Hanmi Pharm. Co., Ltd. | Płynna formuła koniugatu białka zawierająca oksyntomodulinę i fragment immunoglobulinowy |
| WO2014096149A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 Derivatives |
| BR112015023071A2 (pt) | 2013-03-14 | 2017-07-18 | Univ Indiana Res & Tech Corp | conjugados de insulina-incretina |
| EP2986314A4 (en) * | 2013-03-15 | 2016-04-13 | Univ Indiana Res & Tech Corp | PRODRUGS WITH EXTENDED EFFECT |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| WO2015157508A1 (en) * | 2014-04-09 | 2015-10-15 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with pth activity |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
| CN107001441A (zh) | 2014-09-24 | 2017-08-01 | 印第安纳大学研究及科技有限公司 | 脂质化的基于酰胺的胰岛素前药 |
| TN2017000148A1 (en) * | 2014-10-24 | 2018-10-19 | Merck Sharp & Dohme | Co-agonists of the glucagon and glp-1 receptors |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| JOP20200119A1 (ar) | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| JP6344348B2 (ja) | 2015-09-14 | 2018-06-20 | 株式会社デンソー | バッファ制御装置、通信ノード、及び中継装置 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US10793615B2 (en) | 2015-10-27 | 2020-10-06 | Merck Sharp & Dohme Corp. | Long-acting co-agonists of the glucagon and GLP-1 receptors |
| WO2017160669A1 (en) * | 2016-03-18 | 2017-09-21 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
| WO2017214543A1 (en) | 2016-06-09 | 2017-12-14 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
| US11111271B2 (en) | 2016-09-28 | 2021-09-07 | Cohbar, Inc. | Therapeutic peptides |
| CN106986924A (zh) * | 2017-03-23 | 2017-07-28 | 中国药科大学 | 胃泌酸调节素（oxm）类似物及其应用 |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| US11590237B2 (en) | 2017-05-18 | 2023-02-28 | Merck Sharp & Dohme Llc | Pharmaceutical formulation comprising incretin-insulin conjugates |
| PE20200678A1 (es) | 2017-06-16 | 2020-06-11 | Zealand Pharma As | Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2) |
| RU2721282C2 (ru) * | 2017-11-21 | 2020-05-18 | Илья Владимирович Духовлинов | Способ лечения рассеянного склероза (варианты) |
| JP2018090636A (ja) * | 2018-03-15 | 2018-06-14 | インペリアル・イノベイションズ・リミテッド | 新規化合物及び摂食行動に対するそれらの効果 |
| MX2021008979A (es) | 2019-01-28 | 2021-11-12 | Cohbar Inc | Peptidos terapeuticos. |
| EP4058465A1 (en) | 2019-11-14 | 2022-09-21 | Cohbar Inc. | Cxcr4 antagonist peptides |
| KR102446310B1 (ko) | 2020-07-22 | 2022-09-23 | 노보 노르디스크 에이/에스 | 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제 |
| IL302159A (en) | 2020-11-06 | 2023-06-01 | Novo Nordisk As | GLP-1 drug inhibitors and uses thereof |
| KR20220092446A (ko) * | 2020-12-24 | 2022-07-01 | 한미약품 주식회사 | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN119325387A (zh) * | 2022-04-18 | 2025-01-17 | 韩美药品株式会社 | 用于预防或治疗肠病的GLP-2与促胰岛素肽、TNFα抑制剂或两者的组合疗法 |
| EP4522220A1 (en) | 2022-05-10 | 2025-03-19 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
| WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
| WO2025147621A1 (en) * | 2024-01-05 | 2025-07-10 | Indiana University Research And Technology Corporation | Glucagon/glp-1/gip tri-agonists and their associated prodrugs |
Family Cites Families (146)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3740385A (en) * | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| DK119785D0 (da) | 1985-03-15 | 1985-03-15 | Nordisk Gentofte | Insulinpraeparat |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
| DE69020143T2 (de) | 1989-02-17 | 1996-01-25 | Chiron Mimotopes Pty Ltd | Verfahren zur verwendung und herstellung von peptiden. |
| EP0512042B1 (en) * | 1990-01-24 | 1998-04-08 | BUCKLEY, Douglas I. | Glp-1 analogs useful for diabetes treatment |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| IL121070A (en) | 1995-10-12 | 2004-06-20 | Supergen Inc | LIPOSOME FORMULATIONS OF 5beta STEROIDS |
| US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
| EP0879279A4 (en) | 1996-02-06 | 2000-07-12 | Lilly Co Eli | DIABETE TREATMENT |
| JP2000516912A (ja) | 1996-06-05 | 2000-12-19 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | エキセンジン類似体、それらの製造方法およびそれらを含有する製剤 |
| KR20000036015A (ko) * | 1996-09-09 | 2000-06-26 | 스타이니스 에바 | 알파-히드록시산 링커를 함유하는 펩티드 프로드럭 |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| EP1950224A3 (en) | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| EP1119625B1 (en) | 1998-10-07 | 2005-06-29 | Medical College Of Georgia Research Institute, Inc. | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| CN1495198A (zh) | 1998-12-07 | 2004-05-12 | �о���Ӧ�ÿ�ѧЭ��ɷ�����˾ | 胰高血糖素样肽-1的类似物 |
| AU3033500A (en) | 1999-01-15 | 2000-08-01 | Agouron Pharmaceuticals, Inc. | Non-peptide glp-1 agonists |
| DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| AUPQ661800A0 (en) | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
| KR20020097236A (ko) | 2000-04-27 | 2002-12-31 | 바이오네브라스카, 인코포레이티드 | 타입-2 당뇨병, 내당능 장애, 또는 공복 혈당 장애에 대한감수성을 검출하기 위한 위억제성 폴리펩티드 진단 시험 |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| AU2001269833A1 (en) | 2000-06-14 | 2001-12-24 | Cytovax Biotechnologies, Inc. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
| EA008837B1 (ru) | 2000-06-16 | 2007-08-31 | Эли Лилли Энд Компани | Аналоги глюкагоноподобного пептида и их применение |
| AU2001279526A1 (en) | 2000-08-02 | 2002-02-13 | Theratechnologies Inc. | Modified peptides with increased potency |
| AU2001284697A1 (en) | 2000-08-04 | 2002-02-18 | Dmi Biosciences, Inc. | Method of synthesizing diketopiperazines |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| WO2003079972A2 (en) | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| WO2002048192A2 (en) | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| JP2005502322A (ja) | 2001-04-19 | 2005-01-27 | ザ スクリップス リサーチ インスティテュート | 非天然アミノ酸のインビボ組込み |
| DE60228972D1 (de) | 2001-07-31 | 2008-10-30 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| EP1572885A2 (en) | 2001-08-08 | 2005-09-14 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| EP1432430A4 (en) | 2001-08-28 | 2006-05-10 | Lilly Co Eli | PREMIXTURES OF GLP-1 AND BASALINSULIN |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| KR20040054729A (ko) | 2001-10-18 | 2004-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도 |
| CN1571676A (zh) | 2001-10-19 | 2005-01-26 | 伊莱利利公司 | Glp－1和胰岛素的双相混合物 |
| PL374949A1 (en) | 2001-12-20 | 2005-11-14 | Eli Lilly And Company | Insulin molecule having protracted time action |
| EP1461069A2 (en) | 2001-12-29 | 2004-09-29 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| JP4282485B2 (ja) | 2002-01-08 | 2009-06-24 | イーライ リリー アンド カンパニー | 伸長グルカゴン様ペプチド−１アナログ |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| EP1575490A4 (en) | 2002-06-04 | 2007-08-08 | Lilly Co Eli | MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) |
| EP1515746A2 (en) | 2002-06-11 | 2005-03-23 | Eisai Co. Ltd | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| CA2489323A1 (en) | 2002-06-15 | 2003-12-24 | Enteromed, Inc. | Treatment of non-alcoholic fatty liver disease |
| FR2842209B1 (fr) | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
| AU2004231461B2 (en) * | 2003-03-19 | 2009-11-12 | Eli Lilly And Company | Polyethelene glycol linked GLP-1 compounds |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| EP1633384B1 (en) | 2003-05-15 | 2012-03-14 | Trustees Of Tufts College | Stable analogs of glp-1 |
| EP1633390B1 (en) | 2003-06-03 | 2012-01-18 | Novo Nordisk A/S | Stabilized pharmaceutical glp-1 peptide compositions |
| EP1633391B1 (en) | 2003-06-03 | 2011-10-19 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| MXPA05013565A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
| WO2004111078A2 (en) | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Compounds that modulate the glucagon response and uses thereof |
| AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| CN100444898C (zh) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
| EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
| WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
| US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| CA2549582A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US20080139481A1 (en) | 2004-06-17 | 2008-06-12 | Dix Thomas A | Non-Natural Amino Acids |
| US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| EA011653B1 (ru) | 2005-02-11 | 2009-04-28 | Амилин Фармасьютикалз, Инк. | Аналоги и гибридные полипептиды gip с избираемыми свойствами |
| WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| BRPI0609676A2 (pt) | 2005-05-13 | 2011-10-18 | Lilly Co Eli | composto de glp-1 peguilado,e, uso do mesmo |
| DK1891105T3 (da) | 2005-06-13 | 2012-07-16 | Imp Innovations Ltd | Hidtil ukendte forbindelser og deres påvirkninger på spiseadfærd |
| EP1943274A2 (en) | 2005-09-08 | 2008-07-16 | Uutech Limited | Treatment of diabetes related obesity |
| AU2006287531A1 (en) | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of T3 and T4 with enhanced bioavailability |
| EP1937716A2 (en) | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| JP2009527526A (ja) | 2006-02-21 | 2009-07-30 | ノボ・ノルデイスク・エー／エス | 単鎖インスリンのアナログとその製薬的製剤 |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| US20090054305A1 (en) | 2006-03-15 | 2009-02-26 | Novo Nordisk A/S | Mixtures of Amylin and Insulin |
| JP5412273B2 (ja) * | 2006-03-21 | 2014-02-12 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | ペプチド−ぺプチダーゼ阻害剤及びその使用 |
| WO2007124461A2 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compounds |
| WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
| CA2660835A1 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
| WO2008023050A1 (en) | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| KR20090060294A (ko) | 2006-09-08 | 2009-06-11 | 암브룩스, 인코포레이티드 | 변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도 |
| DE102006052755A1 (de) | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
| WO2008076933A2 (en) | 2006-12-14 | 2008-06-26 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| JP5890085B2 (ja) | 2007-01-05 | 2016-03-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 |
| KR20090119876A (ko) * | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| WO2009023270A2 (en) | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| ES2672770T3 (es) | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
| JP2010538069A (ja) | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | エキセンディン−４およびエキセンディン−３の類似体 |
| EP2200635A1 (en) | 2007-09-11 | 2010-06-30 | Novo Nordisk A/S | Mixture comprising an amylin peptide and a protracted insulin |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| AU2008318876B2 (en) | 2007-10-30 | 2014-05-15 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
| EP2217701B9 (en) | 2007-10-30 | 2015-02-18 | Indiana University Research and Technology Corporation | Glucagon antagonists |
| WO2009059278A1 (en) | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| EP2217265B1 (en) | 2007-11-20 | 2017-05-10 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| JP5588354B2 (ja) | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー／エス | 自己切断可能なリンカーを含むプロドラッグ |
| CL2009001425A1 (es) | 2008-06-17 | 2010-04-30 | Univ Indiana Res & Tech Corp | Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal. |
| NZ589847A (en) | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| EP2307037A4 (en) | 2008-06-17 | 2011-08-03 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS |
| US20110144306A1 (en) | 2008-07-23 | 2011-06-16 | President And Fellows Of Harvard College | Ligation of stapled polypeptides |
| US8697632B2 (en) | 2008-12-19 | 2014-04-15 | Indiana University Research And Technology Corporation | Amide based insulin prodrugs |
| CA2747499A1 (en) * | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| RU2578591C2 (ru) | 2008-12-19 | 2016-03-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Лекарственные средства, связанные с дипептидами |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| KR20130111923A (ko) | 2010-05-13 | 2013-10-11 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| RU2604067C2 (ru) | 2010-05-13 | 2016-12-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие активностью относительно ядерных гормональных рецепторов |
| WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
-
2009
- 2009-12-18 CA CA2747499A patent/CA2747499A1/en not_active Abandoned
- 2009-12-18 KR KR1020117016193A patent/KR20110110174A/ko not_active Abandoned
- 2009-12-18 CN CN2009801573173A patent/CN102325539A/zh active Pending
- 2009-12-18 AU AU2009327418A patent/AU2009327418A1/en not_active Abandoned
- 2009-12-18 AR ARP090104993A patent/AR074811A1/es not_active Application Discontinuation
- 2009-12-18 WO PCT/US2009/068745 patent/WO2010071807A1/en not_active Ceased
- 2009-12-18 SG SG2011045283A patent/SG172291A1/en unknown
- 2009-12-18 US US13/130,962 patent/US8969288B2/en active Active
- 2009-12-18 JP JP2011542487A patent/JP2012512903A/ja active Pending
- 2009-12-18 RU RU2011129784/04A patent/RU2550696C2/ru not_active IP Right Cessation
- 2009-12-18 BR BRPI0922969A patent/BRPI0922969A2/pt not_active IP Right Cessation
- 2009-12-18 PE PE2011001238A patent/PE20120332A1/es not_active Application Discontinuation
- 2009-12-18 TW TW098143717A patent/TWI489992B/zh not_active IP Right Cessation
- 2009-12-18 EP EP09833836A patent/EP2376097A4/en not_active Ceased
- 2009-12-18 EP EP16164599.9A patent/EP3075385A1/en not_active Withdrawn
- 2009-12-18 MX MX2011006524A patent/MX2011006524A/es active IP Right Grant
-
2011
- 2011-05-24 IL IL213113A patent/IL213113A/en not_active IP Right Cessation
- 2011-06-17 CL CL2011001498A patent/CL2011001498A1/es unknown
-
2015
- 2015-05-07 JP JP2015095017A patent/JP2015180649A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012512903A5 (enExample) | ||
| RU2011129784A (ru) | Основанные на амидах пролекарства пептидов глюкагонового надсемейства | |
| KR102440323B1 (ko) | 인크레틴 유사체 및 그의 용도 | |
| JP7211712B2 (ja) | グルカゴン受容体アゴニスト | |
| RU2012153753A (ru) | Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов | |
| CN104945500B (zh) | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 | |
| RU2580317C2 (ru) | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов | |
| ES2351661T3 (es) | Péptido-2 análogo al glucagón. | |
| TWI554518B (zh) | 升糖素／ｇｌｐ－１受體共促效劑 | |
| DK2864350T3 (en) | ANALOGUE OF GLUCAGON EXPRESSING GIP RECEPTOR ACTIVITY | |
| RU2014117678A (ru) | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью | |
| JP2013518115A5 (enExample) | ||
| JP2013533849A5 (enExample) | ||
| US20160058881A1 (en) | Prodrugs with prolonged action | |
| US20140107021A1 (en) | Glucagon antagonist-gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity | |
| RU2012153755A (ru) | Пептиды глюкагонового суперсемейства, обладающее активностью относительно ядерных гормональных рецепторов | |
| CA2877358A1 (en) | Glucagon analogs exhibiting gip receptor activity | |
| JP2013534906A5 (enExample) | ||
| CN103003300A (zh) | Glp-1受体激动剂和胃泌素的肽缀合物及其用途 | |
| JP2011524420A5 (enExample) | ||
| TW200938225A (en) | Ester-based peptide prodrugs | |
| CA2904332A1 (en) | Insulin-incretin conjugates | |
| JP2011502159A5 (enExample) | ||
| TW201130503A (en) | Glucagon/GLP-1 receptor co-agonists | |
| WO2024213022A1 (zh) | 肠促胰素类似物及其制备方法和应用 |